Subvisible Particulate Matter: The Count Is a Method, Not a Number
Every other value on a certificate of analysis behaves like a property of the material. Purity is a property. Content mass is a property. Water content is a property, at least at the moment of measurement. Change the instrument and the number moves a little, within the uncertainty the method carries.
Subvisible particulate matter does not behave that way, and the compendium says so in writing. USP General Chapter 〈787〉, which governs subvisible particulates in biotechnology-derived protein and peptide injections, gives limits for the light obscuration method, then directs the reader to Chapter 〈788〉 for the limits of the membrane microscopic method — and states that the two methods “are not equivalent” and “cannot be considered interchangeable.” Two compendial methods, applied to one sample, are not expected to agree.
That is an unusual thing for a pharmacopeia to admit, and it is the single most useful fact a researcher can hold about particle counts. The rest of this article is about why the disagreement exists, how large it is in the published record, and what follows for a lyophilized research vial such as our GHK-Cu 50MG reference material, whose certificate — report DBAV-GHK-Cu-50-062226, lot 5816 — carries a mass value of 53.18 mg, a purity of 99.56% by HPLC-UV, and no particulate row of any kind.
What the limits actually are
For small-volume injections, 〈788〉 sets two numbers per container by light obscuration: not more than 6,000 particles at or above 10 µm, and not more than 600 at or above 25 µm. By the membrane microscopic method the same container must meet 3,000 and 300. Large-volume preparations are governed per milliliter instead, at 25 and 3.
The microscopic limits are half the obscuration limits. That is not a stricter standard applied for its own sake — it is an explicit acknowledgment inside the standard that the two techniques return different numbers from the same vial, and that a single set of limits would therefore be meaningless. 〈787〉 adds a practical concession for protein and peptide products, permitting test aliquots as small as 0.2 mL where 〈788〉 assumes far more material, because a biologic vial rarely contains enough solution to run the classical test at all.
Two thresholds, 10 and 25 µm, and nothing below. That boundary is where the argument in the literature begins.
Why light obscuration undercounts protein and peptide particles
Light obscuration measures a shadow. A particle crosses a laser beam, the detector records a drop in transmitted light, and the size is inferred from how much light went missing. The inference is calibrated with polystyrene microspheres.
Polystyrene has a refractive index of about 1.59. Protein aggregates, as Sharma, King, Oma and Merchant reported in The AAPS Journal in 2010, sit between roughly 1.33 and 1.40 — close enough to water that they cast a faint shadow for their size. The instrument does not know it is looking at something translucent. It reports a smaller particle, or no particle at all.
The magnitude of that error is not subtle. In the same work, concentrations measured by flow imaging and by light obscuration for particles in the 〈788〉 size range “differed by one or more orders of magnitude and became larger as the particle size increased,” and in filtrate studies flow imaging measured “more particles (by two orders of magnitude) than LO.” In opalescent monoclonal antibody formulations at around 60 mg/mL, transparent protein particles were “significantly underestimated by the LO and manual microscopic technique, particularly those in the 2–10-µm size range.” When the carrier fluid’s refractive index was raised to about 1.37, flow imaging sizing was “almost unaffected” while light obscuration showed “significant under-sizing.”
Zölls and colleagues took that observation to its conclusion in the Journal of Pharmaceutical Sciences in 2013. Having measured a refractive index of 1.41 for protein particles from two different proteins, they showed that raising formulation refractive index — with high protein concentration, or with sugars at ordinary pharmaceutical levels — progressively suppressed counts, and that at a refractive index match the particles became “invisible” to the system: no longer detectable by light obscuration or by flow imaging. Not undercounted. Absent.
Their recommendation was to check the effect deliberately using polytetrafluoroethylene particles as a probe, and to bring in a light-independent technique such as resonant mass measurement whenever the matrix looks likely to interfere.
The range nobody is required to count
Carpenter, Randolph, Jiskoot and colleagues had already made the structural argument in the Journal of Pharmaceutical Sciences in 2009, under a title that says the thesis plainly: overlooking subvisible particles in therapeutic protein products, gaps that may compromise product quality. Compendial limits begin at 10 µm. Size-exclusion chromatography, the standard aggregation assay, resolves species several orders of magnitude smaller. Between them sits a band that neither routine method interrogates and no monograph requires anyone to report.
The instrumentation has since improved — flow imaging, resonant mass measurement and backgrounded membrane imaging all address parts of that band — but none of it is compendial for release, and none of it appears on a certificate of analysis in this industry. Reproducibility across laboratories remains an active question in its own right; Ripple, Montgomery and Hu published an interlaboratory comparison of sizing and counting of subvisible particles designed to mimic protein aggregates in the Journal of Pharmaceutical Sciences in 2015 for exactly that reason.
The problem specific to a lyophilized research vial
Here is where the compendial framework and a research peptide vial part company entirely.
〈787〉 and 〈788〉 both test an injection — a solution. Our vials do not contain a solution. They contain lyophilized powder, and a powder has no subvisible particle count in the compendial sense, because the measurement requires a liquid moving through a flow cell.
The count therefore does not exist until someone makes it exist, and whoever reconstitutes the vial is the one who does. Their diluent, their filtration status, their stopper puncture, their swirl or shake, their hold time before the sample reaches the instrument — all of it is inside the measurement. This is not a supplier evading a test. It is a structural feature of the dosage form: for a lyophilized article, the particulate result is jointly produced by the vial and the laboratory, and no certificate issued before reconstitution can speak for the second half of that.
There is a further wrinkle for this particular SKU, and it is worth stating precisely because it is easy to overstate. GHK-Cu is the only compound in our catalog whose certificate records an appearance other than white lyophilized powder; lot 5816 is recorded as blue powder, which is the visible absorption of the coordinated copper(II) center. Both light obscuration and flow imaging are optical methods whose output depends on the contrast between particle and medium. A visibly colored solution is not a neutral matrix for either technique. What the published work above establishes is that matrix optics change the answer; what nobody has published is a light obscuration or flow imaging dataset for a copper-peptide solution, and we are not going to model one and present it as data.
What this means when reading any certificate in this category
Three things follow, and they are all defensive rather than reassuring.
A missing particulate row is not a hidden failure. No certificate we have read in this category — ours or a competitor’s — carries subvisible particulate data. Our certificates contain a sample identification block, an HPLC-UV purity and content section, an appearance line and a digital verification block. Nothing else. A supplier who claims a 〈788〉 pass on a lyophilized vial is claiming a test that would have to have been run on a solution somebody made.
A particulate number without its method is not information. If a certificate ever does carry one, the method, the instrument, the diluent, the aliquot volume and the calibration standard all have to come with it, or the number cannot be compared to anything — including the same product’s next lot.
Visual inspection is the honest floor. Visible particulates are a different category from subvisible ones and are assessed by eye. That check remains worth making, and it is the reason our content uniformity and storage articles treat appearance as a real observation rather than boilerplate. It is a floor, not a characterization, and the distinction should not be blurred.
Domestic supply does not change the physics here. What it changes is the length of the undocumented interval before the vial reaches a US bench: material shipped same-day from our Santa Barbara facility under a single Wyoming entity, with a batch certificate tied to the lot in the box, gives a laboratory a documented starting point and a short custody chain. The particulate question then begins where it always begins — at reconstitution, in that laboratory’s own hands.
References
- USP General Chapter 〈787〉, Subvisible Particulate Matter in Therapeutic Protein Injections — scope, sample volume allowance, light obscuration limits, and the statement that the compendial methods are not interchangeable.
- USP General Chapter 〈788〉, Particulate Matter in Injections — light obscuration and membrane microscopic limits for small-volume and large-volume preparations.
- Sharma DK, King D, Oma P, Merchant C — micro-flow imaging: flow microscopy applied to sub-visible particulate analysis in protein formulations. The AAPS Journal, 2010; 12(3):455–464. DOI 10.1208/s12248-010-9205-1.
- Zölls S, Gregoritza M, Tantipolphan R, Wiggenhorn M, Winter G, Friess W, Hawe A — how subvisible particles become invisible, and the relevance of the refractive index for protein particle analysis. Journal of Pharmaceutical Sciences, 2013. DOI 10.1002/jps.23479.
- Carpenter JF, Randolph TW, Jiskoot W, et al. — overlooking subvisible particles in therapeutic protein products. Journal of Pharmaceutical Sciences, 2009; 98(4):1201–1205. DOI 10.1002/jps.21530. PMID 18704929.
- Ripple DC, Montgomery CB, Hu Z — an interlaboratory comparison of sizing and counting of subvisible particles mimicking protein aggregates. Journal of Pharmaceutical Sciences, 2015; 104(2):666–677. DOI 10.1002/jps.24287.
- Maple Research Labs batch certificate DBAV-GHK-Cu-50-062226, lot 5816, issued by Testides Analytical; read directly from the certificate linked on the product page.
Reference 4 is cited without volume and page numbers because the primary record reached this run without them; the DOI is exact. References 5 and 6 are cited at title level — the full texts were not retrievable, so no figures are quoted from them.
All materials supplied by Maple Research Labs are provided for research use only. They are not for human use, not for veterinary use, and not for diagnostic or therapeutic application. Nothing in this article describes administration to people.